mdl-100907 and Central-Nervous-System-Diseases

mdl-100907 has been researched along with Central-Nervous-System-Diseases* in 2 studies

Reviews

1 review(s) available for mdl-100907 and Central-Nervous-System-Diseases

ArticleYear
5-HT2C receptor modulators: a patent survey.
    Expert opinion on therapeutic patents, 2010, Volume: 20, Issue:11

    The 5-HT(2C) receptor is a GPCR and is one of the 14 subtypes that constitute the serotonin receptor family. The 5-HT₂(C) receptor is exclusively expressed in the CNS where it demonstrates a wide distribution and displays high-affinity interactions with a wide variety of psychiatric medications. Modulators of 5-HT₂(C) have been implicated as a potential treatment for diseases of significant unmet medical need, including obesity, schizophrenia, depression, anxiety, Parkinson's disease, drug addiction, erectile dysfunction and urinary incontinence. Thus, there is a great interest in developing potent and selective 5-HT₂(C) receptor modulators.. This review article highlights the research progress in 5-HT₂(C) receptor modulators published in the patent literature between January 2003 and June 2010, giving emphasis to the medicinal chemist's standpoint.. Readers will rapidly gain an overview of the various 5-HT₂(C) receptor modulators reported in the patent literature in the past 8 years. Furthermore, the readers will learn which structure type can interact with the 5-HT₂(C) receptor. In addition, the readers will be aware of the pharmaceutical companies that have been the main players in the field.. There is substantial evidence supporting the concept that a selective 5-HT₂(C) receptor modulator should provide benefit in the treatment of a variety of CNS disorders. Although research efforts have identified several promising 5-HT₂(C) receptor modulators that display high functional selectivity, further clinical efficacy and safety data are needed to prove their actual clinical utility. Therefore, the query for selectively acting 5-HT₂(C) receptor modulators is still ongoing.

    Topics: Animals; Central Nervous System Diseases; Drug Delivery Systems; Drug Design; Drug Industry; Drug Inverse Agonism; Humans; Patents as Topic; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists

2010

Other Studies

1 other study(ies) available for mdl-100907 and Central-Nervous-System-Diseases

ArticleYear
Serotonin in the pathophysiology and treatment of CNS disorders.
    Experimental brain research, 2013, Volume: 230, Issue:4

    Topics: Animals; Central Nervous System Diseases; Humans; Receptors, Serotonin, 5-HT2; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists

2013